Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.
Actively Recruiting
Researchers are conducting a low-intervention, prospective study to explore the inflammatory, functional, and clinical differences between patients who have asthma alone and those who have both asthma and primary arterial hypertension. The goal is to improve understanding of asthma and its related health conditions, focusing on how these diseases may interact. This observational research is sponsored by Istituti Clinici Scientifici Maugeri SpA. Participants will not receive experimental treatments but will undergo measurements of inflammatory markers, such as Interleukin 4, 5, and 13, and lung function tests including FEV1. These assessments will occur at the start of the study and again after four years to monitor changes over time. The study includes two groups patients with asthma and patients with both asthma and hypertension. Participants will be involved in clinical evaluations and complete questionnaires measuring asthma control at baseline and after four years. Researchers will track inflammatory and lung function markers to better understand disease progression and interactions. The study spans several years, with primary outcomes measured at two time points, helping to assess long-term changes in health status related to asthma and hypertension.
Actively Recruiting
Researchers are conducting a prospective observational study to develop and validate an Italian version of the Waddell Disability Index WDI-I, a questionnaire that patients complete themselves to assess disability related to chronic low back pain. Low back pain is a major cause of disability worldwide, and patient-reported outcome measures like the WDI are important tools for clinical assessment and rehabilitation planning. This study addresses the need for a culturally adapted Italian version of this well-known tool. The study involves a careful translation process including forward and backward translations by bilingual experts, review by a panel of clinicians, and pilot testing with patients. After finalizing the Italian version, 115 adults with chronic low back pain lasting at least three months will complete the WDI-I along with other established pain and disability scales. The WDI-I will be completed again after 7 to 10 days to evaluate consistency over time. Participants will provide demographic and clinical data and complete questionnaires including the WDI-I, Numeric Pain Rating Scale, Italian Oswestry Disability Index, and Italian Pain Catastrophizing Scale. Researchers will analyze internal consistency, reliability, and validity of the WDI-I using statistical methods. Patient data will be pseudonymized and securely handled. The study will run until late 2026, aiming to offer a reliable and valid Italian tool for assessing disability in chronic low back pain.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Chronic Obstructive Pulmonary Disease COPD causes exercise intolerance and difficulty performing daily activities due to symptoms like breathlessness and fatigue. This research evaluates whether adding upper limb endurance training to the usual lower limb rehabilitation improves patients ability to perform daily tasks, compared to the standard lower limb training alone. The study is a randomized controlled trial aiming to improve exercise tolerance and quality of life in COPD patients. Participants will be assigned to one of two rehabilitation programs lasting 14 daily sessions of 90 minutes each. One group will perform lower limb training on a stationary bike plus strengthening exercises. The other group will combine lower limb cycling, arm ergometer training, and strengthening exercises for both upper and lower limbs. All sessions will be supervised by physiotherapists, and education about disease management will be provided. Throughout the study, participants will undergo clinical evaluations including lung function tests, blood gas analysis, and quality of life questionnaires. The main measurement is the time taken to complete the GLITTRE test, assessing daily living activities, evaluated from randomization to the end of the program up to 16 days. Secondary outcomes include changes in effort tolerance for upper and lower limbs and energy cost of walking. Safety and progress will be monitored during the rehabilitation period.
Actively Recruiting
Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an instrumented stair climb test designed to assess the ability to climb and descend stairs in both children and adults with various conditions including cerebral palsy, limb amputation, Parkinsons disease, stroke, and joint arthroplasty. The study aims to characterize and compare the stair climbing performance among these groups and healthy individuals, while exploring correlations between the objective measurements from wearable sensors and standard clinical scales. This research also seeks to test the feasibility and reliability of this instrumented stair climb test on healthy subjects. Participants will perform an instrumented test involving climbing and descending a flight of 10-12 steps, using wearable sensors to capture kinematic and electromyographic data. The study includes healthy children, adults, and elderly groups, as well as groups with specific diagnoses. Additional assessments such as the 10-meter walk test, 30-second chair stand test, Timed Up & Go test, and Borg scale are also used to evaluate walking speed, leg strength, balance, and perceived effort. Some tests involve repeating the stair climb with repositioning of sensors to assess reliability. During the study, participants will be monitored for intra- and inter-operator variability and the absolute error in test timing over approximately one year. Researchers will collect data from the instrumented stair test and correlate these with clinical functional tests to assess validity. The study involves multiple centers responsible for recruiting and gathering data, with analysis and algorithm development supported by a technical institute. Total participation time varies, with data collection and evaluations conducted under supervised conditions.
Actively Recruiting
Researchers are evaluating the informational needs of caregivers of patients with neuromotor diseases during rehabilitation hospitalization. This study aims to validate a new questionnaire designed to detect and assess these needs throughout the rehabilitation process. The research focuses on the post-acute phase and seeks to improve understanding of caregivers experiences and support requirements from hospital admission to discharge. Caregivers will be given the QBI questionnaire twice once within the first 10 days of the patients admission to the neurorehabilitation unit, and again within 7 days of the patients discharge. The study involves about 300 caregivers from 13 centers, ensuring a comprehensive assessment and validation of the questionnaire by comparing it with other established tools like the CNA and SAT-16. Participants will provide information through the questionnaires at two key points during the patients hospital stay. Researchers will analyze the responses to assess reliability, validity, and consistency of the tool, including test-retest reliability on a subset of caregivers. The study duration is approximately three years, with the primary outcome being the validation of the QBI questionnaire measuring caregiver informational needs from enrollment to the end of rehabilitation, which lasts 2 to 6 months.
Actively Recruiting
Researchers are studying the effects of adding music to rehabilitation training for patients with Chronic Obstructive Pulmonary Disease COPD and chronic respiratory failure CRF. This trial compares usual rehabilitation training to training supported by music, aiming to see if music can improve exercise capacity, endurance, and reduce fatigue and breathlessness. Previous studies suggest music may help reduce symptoms like anxiety and dyspnea and improve quality of life for COPD patients during exercise. Participants will be randomly assigned to one of two groups a music-supported training group or a usual training group without music. The music group listens to selected music styles with a constant rhythm designed to synchronize with cycling exercise sessions lasting about 30 minutes. Both groups perform supervised training on a cycle ergometer, with the only difference being the presence or absence of music. Training occurs 5 to 6 times per week over 12 to 14 sessions. Throughout the study, participants will undergo various assessments including lung function tests, 6-minute walk tests, muscle strength measurements, blood gas analysis, and exercise endurance tests. Heart rate, oxygen saturation, and breathlessness levels will be monitored before and after each session. The primary outcome is the change in walking test performance after up to three weeks of training, with additional evaluations of breathlessness, fatigue, and disease impact on daily activities. Safety, adherence, and reasons for withdrawal will also be tracked by the study team.
1-10 of 11
1